JANE STREET GROUP, LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 127 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.

Quarter-by-quarter ownership
JANE STREET GROUP, LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$49,623
+50.3%
42,053
+79.6%
0.00%
Q2 2023$33,022
-96.3%
23,420
-96.1%
0.00%
Q1 2023$894,666
+441.4%
596,444
+322.3%
0.00%
Q4 2022$165,257
+334.9%
141,245
+315.2%
0.00%
Q3 2022$38,000
-59.1%
34,022
-42.3%
0.00%
Q2 2022$93,000
-51.3%
58,977
-52.5%
0.00%
Q1 2022$191,000
-74.9%
124,210
-60.1%
0.00%
Q4 2021$762,000
+382.3%
310,976
+397.2%
0.00%
Q3 2021$158,000
-75.7%
62,549
-72.6%
0.00%
Q2 2021$650,000
+291.6%
228,066
+223.3%
0.00%
Q1 2021$166,000
+207.4%
70,541
+129.7%
0.00%
Q4 2020$54,000
-68.6%
30,715
-83.3%
0.00%
Q3 2020$172,000
-80.2%
183,740
-81.6%
0.00%
-100.0%
Q2 2020$867,000
+452.2%
996,255
+424.5%
0.00%
Q1 2020$157,000
+265.1%
189,951
+291.9%
0.00%
Q4 2019$43,000
+65.4%
48,468
+85.2%
0.00%
Q3 2019$26,00026,1680.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders